BioCentury
ARTICLE | Clinical News

Neurogen's NGD-91-3 in Phase II to treat anxiety

November 29, 2000 8:00 AM UTC

NRGN partner Pfizer (PFE) began a double-blind Phase II trial of NRGN's NGD-91-3, a small molecule partial GABA agonist, to treat anxiety disorders in which the product will be compared to placebo and...